INDICATION SCREEN & DEVELOPMENT STRATEGY
INDICATION SCREEN & DEVELOPMENT STRATEGY
Situation: A mid-size pharma company has a compound which modulates a novel target involved in various disease processes. They want to comprehensively prioritize indications for lead and follow-on development
Approach: At SCITARIS, we believe that indication selection should be primarily science-driven. Therefore, we used a comprehensive screening approach to prioritize 21k+ indications for fit to the target biology and chosen modality, in addition to taking into account specific company requirements, development and commercial considerations.
Outcome: The company implemented the indication and combination strategy we recommended as the best balance between risk, reward and time to market
